Author

Wilbert B. Copeland

Observed names: W.B. Copeland, Wilbert Copeland

Institution: Bristol-Myers Squibb (United States)

Observed institutions: University of Washington, University of California San Diego, Bristol-Myers Squibb (United States)

ORCID: 0000-0002-9616-6341

Observed ORCID: 0000-0002-9616-6341

OpenAlex ID: A5013364487

Rewiring of Genetic Networks in Response to DNA Damage

2010 · Sourav Bandyopadhyay, Monika Mehta, et al. · Science · 452

Computational tools for metabolic engineering

2012 · Wilbert B. Copeland, Bryan A. Bartley, et al. · Metabolic Engineering · 102

Increasing gender diversity in the STEM research workforce

2019 · Carol W. Greider, Jason M. Sheltzer, et al. · Science · 96

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML

2021 · Amer M. Zeidan, Isaac Boss, et al. · Blood Advances · 90

Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study

2019 · Amer M. Zeidan, James Cavenagh, et al. · Blood · 83

Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials

2020 · Samuel A. Danziger, Mark McConnell, et al. · PLoS Medicine · 79

Mathematical modeling and synthetic biology

2008 · D. Chandran, W.B. Copeland, et al. · Drug Discovery Today Disease Models · 59

Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma

2021 · Mary H. Young, Greg Pietz, et al. · Scientific Reports · 9

Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies

2018 · Samuel A Danziger, Mark McConnell, et al. · Blood · 4

Comprehensive Immune Profiling from Peripheral Blood and Bone Marrow in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma Patients Reflects Differences in Immune Subsets and Activation Status

2018 · Greg E. Pietz, Mark Tometsko, et al. · Blood · 3

Deep Immunoprofiling of the Bone Marrow Microenvironmental Changes Underlying the Multistep Progression of Multiple Myeloma

2018 · Mary H Young, Sam A Danziger, et al. · Blood · 2

Biological Probes to Measure Transcription Dynamics in E. coli

2014 · Wilbert B. Copeland · ResearchWorks at the University of Washington (University of Washington) · 2

Deconvolution of the Immune Microenvironment Can Predict the Outcome of Myeloma Patients and Inform Potential Intervention Strategies

2017 · Samuel A. Danziger, Andrew Dervan, et al. · Blood · 1

Do chemical language models provide a better compound representation?

2023 · Mirko Torrisi, Saeid Asadollahi, et al. · bioRxiv (Cold Spring Harbor Laboratory)

Supporting Online Material for Rewiring of Genetic Networks in Response to DNA Damage

2010 · Sourav Bandyopadhyay, Monika Mehta, et al.

Works count: 15

Citation count: 982

H-index: 8

I10-index: 7